Medicines Co. (MDCO): Positive ORION-1 Data Could Bring 2-3x Per Year Dosing - Jefferies
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of The Medicines Company (NASDAQ: MDCO) after the company detailed positive PIIb ORION-1 data investigating inclisiran for hypercholesterolemia at AHA. The analyst stated "Inclisiran at 300 mg demonstrated a mean ~50% LDLC reduction at 3 mo, and a second dose at 3 mo drove LDL reduction close to ~60%. Going forward MDCO believes the dosing freq will be no more than 2-3x per year (bi-/triannual dosing), which we believe is differentiated compared to Repatha and Praluent".
No change to the price target of $43.
Shares of The Medicines Company closed at $36.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Kroger (KR) to $30 Following 3Q and Guidance
- Pivotal Research Downgrades Kroger (KR) to Hold
- Oppenheimer Cuts Price Target on Workday (WDAY) Following 3Q; Reiterates Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!